URL https://clinicaltrials.gov; Unique Identifier NCT04226547.
“From a clinical perspective, CLOSURE-AF reinforces the importance of careful patient selection for LAAO and highlights the continued central role of DOAC therapy in eligible patients. Trials such as the recently published CHAMPION-AF (Watchman Flx versus NOAC for Embolic Protection in the Managem...”
Reddy et al. (Mon,) studied this question.